Teva Pharmaceuticals

Company Overview

Snapshot

Founded in January 1901, Teva Pharmaceuticals operates with over 29,000 employees. The company has raised a total of $908 million across 5 funding rounds from 5 investors. In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences.

Business overview

Teva Pharmaceuticals is a global pharmaceutical company specializing in the development, production, and marketing of generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, the company's extensive product portfolio includes over 3,600 medicines, serving markets worldwide. Teva operates within the Health Tech & Life Sciences sector, focusing on areas such as respiratory, women's health, neurology, and oncology.

Strategic signal

In September 2025, Teva's Emrusolmin was granted U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy. This designation highlights the potential of Emrusolmin to address an unmet medical need and could accelerate its development and review process, signaling a positive trajectory for Teva's specialty pipeline.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Teva Pharmaceuticals?

In September 2025, Teva’s Emrusolmin was granted U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy.

What was a recent product approval for Teva Pharmaceuticals in Canada?

In September 2025, Teva and Medincell’s Risperidone LAI was approved in Canada as LONGAVO®.

What was a recent market launch for Teva Pharmaceuticals?

In September 2025, Teva launched generic Saxenda in the U.S. after receiving FDA approval.